Streetbeat News

DNA

Ginkgo Bioworks Holdings, Inc.

https://www.ginkgobioworks.com

Industry

Biotechnology

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Open

8.30

Mkt cap

472M

Volume

498K

High

8.56

P/E Ratio

-0.47

52-wk high

75.20

Low

8.13

Div yield

N/A

52-wk low

5.26

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) will present its Q3 2024 results on November 12, 2024, post-market. The presentation will include a Q&A session and will be accessible via their investor relations website.

Portfolio Pulse from

November 05, 2024 | 12:30 pm

Ginkgo Bioworks Holdings, Inc. (DNA) experienced a decline of 1.55% in its stock price, closing at $7.63, which was a larger drop compared to the broader market.

Portfolio Pulse from

November 05, 2024 | 12:30 pm

Ginkgo Bioworks has entered a partnership with NOVUS International to develop more efficient and cost-effective enzymes. This collaboration aims to enhance enzyme production capabilities.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 11:19 am

Ginkgo Bioworks has partnered with NOVUS International to develop advanced feed additives for the animal agriculture industry. This collaboration aims to address the evolving needs of the sector.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 11:10 am

TD Cowen analyst Brendan Smith maintains a Buy rating on Ginkgo Bioworks Holdings (NYSE:DNA) and raises the price target from $3 to $10.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 5:01 pm

Ginkgo Bioworks Holdings Inc (NYSE:DNA) shares are rising due to the launch of Ginkgo Datapoints, a product aimed at improving AI model training by generating large biological datasets efficiently. This follows a 10% stock rally after launching a protein large language model with Google Cloud.

Portfolio Pulse from Adam Eckert

September 18, 2024 | 2:14 pm

Ginkgo Bioworks has expanded its partnership with Google Cloud to introduce two AI tools aimed at accelerating drug development. These tools, a protein large language model and a model API, leverage AI and proprietary data to enhance therapeutic discovery. The collaboration with Google Cloud and the development of AlphaFold 3 by Google DeepMind are key components of this initiative.

Portfolio Pulse from Vandana Singh

September 17, 2024 | 5:48 pm

Ginkgo Bioworks shares rose following the launch of a protein LLM and model API on Google Cloud, aimed at speeding up drug development.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 4:19 pm

Ginkgo Bioworks shares surged after announcing a new protein large language model built on Google Cloud, aimed at aiding pharmaceutical and biotech companies in drug development. The model and API are now publicly available, with plans for further expansion.

Portfolio Pulse from Adam Eckert

September 17, 2024 | 3:17 pm

Several US-listed stocks saw significant gains on Tuesday. Compass Minerals rose 24.5% after announcing better-than-expected preliminary Q3 revenue. Talkspace gained 20.9% following a partnership with Amazon Health Services. Gannett rose 14.5% after a Citigroup upgrade. Gevo surged 14% after securing a US patent. Other notable gainers include Ginkgo Bioworks, Designer Brands, and Hewlett Packard Enterprise.

Portfolio Pulse from Avi Kapoor

September 17, 2024 | 2:22 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.